According to the lead author of the study, Dr. Kevin Nead of the University of Pennsylvania Perelman School of Medicine, "In this study, we did find that men who received hormone therapy had about an 88 percent increased risk of Alzheimer's disease.”
Read MoreAccording to the American Cancer Society, prostate cancer is the second leading cause of cancer death in men in the United States, behind lung cancer. It is also the most common type of cancer in men other than skin cancer. And according to the Prostate Cancer Foundation, African-American men are nearly 1.6 times more likely to be diagnosed with prostate cancer than Caucasian men and 2.4 times more likely to die from the disease.
Read More
Research suggests that having high levels of stress may increase a man’s risk of prostate cancer death. This includes men with advanced prostate cancer and localized prostate cancer.
Read MoreA new genetic test has recently become available called Oncotype DX. The test is made by Genomic Health and will now be available at Dr. Samadi's Prostate Cancer Center in New York City. What is Oncotype DX?
Read MoreWhat is Cyberknife? Cyberknife is a form of stereotactic body radiation therapy (SBRT) and robotic-assisted radiosurgery (not actual surgery) that utilizes a computerized robot to automatically deliver high doses of radiation to the prostate gland. Fiducials are implanted into the body so that the Cyberknife machine can adjust to movement during each treatment.
Read MoreCyberknife is an alternative option to treat prostate cancer, as well as many other cancers such as lung, brain, spine, liver and pancreatic cancer. It is not a surgical procedure, but a form of stereotactic body radiation therapy (SBRT) and robotic-assisted radiosurgery that utilizes a computerized robot to automatically deliver high doses of radiation to the prostate gland. For men with prostate cancer, Cyberknife is recommended for men with cancer limited to the prostate, and men with low to moderate risk prostate cancer.
Read MoreA “normal” PSA level is generally between 1.0 and 4.0 ng/mL. Anything above 4.0ng/mL is considered “abnormal” or elevated. The PSA level may differ depending on a man’s age. As men age, the prostate gets larger. A larger prostate produces more PSA. Therefore, younger men generally have lower PSA levels while older men tend to have higher PSA levels. These variations in PSA levels are not always associated with a prostate condition, other than an enlarged prostate. The PSA level may also vary depending on the man’s ethnicity or if they have a family history of prostate cancer.
Read MoreA new genetic test has recently become available called Oncotype DX. The test is made by Genomic Health and will now be available at Dr. Samadi's Prostate Cancer Center in New York City. What is Oncotype DX? The Oncotype DX prostate cancer test is a biopsy-based genetic test that can be combined with other measures to predict the aggressiveness of prostate cancer. The test applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions for each individual patient.
Read MoreConsider these facts on prostate cancer. More than 200,000 men will develop prostate cancer this year, making it the #1 cancer in men after skin cancer. Almost 30,000 men will die of prostate cancer, second only to lung cancer. Detecting and treating prostate cancer early is the key to cure. Unfortunately prostate cancer screening guidelines vary among organizations with no universally accepted standard. As a consequence this has created confusion among patients and caregivers alike. The importance of being an educated patient has never been greater.
Read MoreIf you’re one of the 230,000 men diagnosed with prostate cancer every year, you’re probably dealing with a dilemma of which treatment option to choose. Your doctor has likely spoken with you about radiation and surgery, but how do you choose?
Read MoreThe U.S. Preventive Services Task Force recommends against PSA (prostate specific antigen) screening for prostate cancer. The task force currently gives PSA screening a grade D, meaning that there is moderate or high certainty that the PSA test has no benefit or that the harms outweigh the benefits. This recommendation was first issued in 2011.
Read MoreJune is Men's Health Month and in light of Father's Day, we thought it'd be interesting to put together the top 5 men's health findings from 2015 so far. Here's what you need to know.
Read More
